http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2364985-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2007-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b1c551051f48a55197d317d8a35a0ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b369f88e24f36a3df1520a8b73ab6eed |
| publicationDate | 2011-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2364985-T3 |
| titleOfInvention | DERIVATIVES OF PIRIMIDINE AND QUINAZOLINE AS MODULARS OF THE ACTIVITY OF THE SOMATOSTATIN RECEPTOR. |
| abstract | Compounds of general formula I ** Formula ** in which A is -O- or -NH-; R1 is selected from the group consisting of hydrogen, C1-7 alkoxy and halogen; R 2 is selected from the group consisting of C 2-7 alkyl, C 2-7 alkenyl, halogen-C 1-7 alkyl, C 1-7 alkyl-C 1-7 alkyl, and benzyl; R 3 is selected from the group consisting of hydrogen, C 1-7 alkyl, hydroxy, C 1-7 alkoxy, C 2-7 alkenyloxy, C 1-7 hydroxy-alkoxy, C 1-7 alkoxy-C 1-7 alkoxy, -O-cycloalkyl C3-7, halogen, halogen-C1-7 alkyl, -NR6R7, in which R6 and R7 independently of each other are hydrogen or C1-7 alkyl, -O-SO2-R8 in which R8 is C1-7 alkyl and pyrrolyl; R4 is selected from the group consisting of hydrogen, hydroxy, C1-7 alkoxy, amino, nitro, hydroxy C1-7 alkoxy, C1-7 alkoxy-C1-7 alkoxy, and -O-benzyl; or R3 and R4 are linked together to form a ring together with the carbon atoms to which they are attached and R3 and R4 together are -O-C (CH3) 2-CH = CH-; R5 is selected from the group consisting of hydrogen, halogen, and C1-7 alkoxy; G is selected from the groups in which R9 is selected from the group consisting of hydrogen, C1-7 alkyl, halogen, halogen C1-7 alkyl, amino, phenyl, -OR17, where R17 is hydrogen or C1-7 alkyl , and -C (O) -OR18, wherein R18 is hydrogen or C1-7 alkyl; R10 is selected from the group consisting of hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, halogen C1-7 alkyl, -C (O) -OR19, wherein R19 is hydrogen or C1-7 alkyl, and -NR20R21 , wherein R20 is hydrogen or C1-7 alkyl and R21 is selected from the group consisting of hydrogen, C1-7 alkyl and C1-7 alkylcarbonyl, or in which R20 and R21 together with the nitrogen atom to which they are joined to form a 3, 4, 5, 6 or 7 membered heterocyclic ring; R11 is selected from the group consisting of hydrogen, C1-7 alkyl, C1-7 alkoxy, halogen, halogen C1-7 alkyl, amino, - (CH2) mC (O) -OR22, where m is 0 or 1 and R22 is hydrogen or C1-7 alkyl, phenyloxy, in which the phenyl is substituted or unsubstituted by one to three groups from the group consisting of C1-7 alkyl, C1-7 alkoxy, halogen and halogen C1-7 alkyl, and - (CH2) n-phenyl, wherein n is 0 or 1 and phenyl is substituted or unsubstituted by one to three groups from the group consisting of C1-7 alkyl, C1-7 alkoxy, halogen and halogen alkyl C1-7; R12 is selected from the group consisting of hydrogen, C1-7 alkyl, halogen, halogen C1-7 alkyl, amino, phenyl, -OR23, wherein R23 is hydrogen or C1-7 alkyl, and -C (O) -OR24, wherein R24 is hydrogen or C1-7 alkyl; R13, R14, R15 and R16 independently of each other are selected from the group consisting of hydrogen, C1-7 alkyl, halogen, hydroxy, and C1-7 alkoxy; and pharmaceutically acceptable salts thereof. |
| priorityDate | 2006-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 875.